CRADD as A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: CRADD

NCBI ID: G8738

CRADD

CRADD as A Potential Drug Target and Biomarker for Neurodegenerative Diseases

CRADD (CRADD-HUMAN) is a protein that is expressed in the human brain and is known for its role in the development and progression of neurodegenerative diseases. The protein is composed of two domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain.

The N-terminal transmembrane domain of CRADD is known as the extracellular domain (ECD) and is responsible for the protein's ability to interact with extracellular molecules such as ligands and other proteins that are located outside of the cell membrane. This allows CRADD to play a role in various signaling pathways that are important for the development and progression of neurodegenerative diseases.

The C-terminal cytoplasmic domain of CRADD is known as the intracellular domain (ICD) and is responsible for the protein's ability to interact with other proteins that are located within the same cell. This allows CRADD to play a role in various cellular processes that are important for the development and progression of neurodegenerative diseases.

One of the most promising aspects of CRADD is its potential as a drug target. The N-terminal transmembrane domain of CRADD is known to be involved in the development and progression of neurodegenerative diseases, and therefore, it can be targeted using small molecules or antibodies to inhibit its activity.

CRADD has also been shown to be a potential biomarker for the diagnosis and prognosis of neurodegenerative diseases. The levels of CRADD have been shown to be decreased in individuals with neurodegenerative diseases, and therefore, it can be used as a diagnostic tool to determine the severity of a neurodegenerative disease. Additionally, CRADD has also been shown to have a relationship with the progression of neurodegenerative diseases, which can be used as a biomarker to track the disease's progression.

In addition to its potential as a drug target and biomarker, CRADD is also of interest to researchers as a potential target for therapeutic intervention. Studies have shown that CRADD can be targeted using small molecules and antibodies, which suggests that it may be a promising target for neurodegenerative disease treatment.

Overall, CRADD is a protein that has the potential to be a drug target and biomarker for the development and progression of neurodegenerative diseases. Further research is needed to fully understand its role and its potential as a therapeutic intervention.

Protein Name: CASP2 And RIPK1 Domain Containing Adaptor With Death Domain

Functions: Adapter protein that associates with PIDD1 and the caspase CASP2 to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis (PubMed:9044836, PubMed:15073321, PubMed:16652156, PubMed:17159900, PubMed:17289572). Also recruits CASP2 to the TNFR-1 signaling complex through its interaction with RIPK1 and TRADD and may play a role in the tumor necrosis factor-mediated signaling pathway (PubMed:8985253)

The "CRADD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRADD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets